Key Highlights
- Loss per share was USD 0.08 against an estimate of a USD 0.05 loss.
- Net loss was USD 9.71 million, compared with USD 9.88 million.
- Research and development expenses were USD 5.15 million, compared with USD 5.08 million.
- Cash and cash equivalents were USD 2.43 million at September 30, 2026.
Oncolytics Biotech (NASDAQ:ONCY) reported a net loss of USD 9.71 million for the third quarter of 2026, compared with USD 9.88 million in the prior-year quarter. Basic and diluted net loss per share was USD 0.08, compared with USD 0.10, against an estimate of a USD 0.05 loss.
For the nine months ended September 30, 2026, the net loss was USD 28.39 million, compared with USD 19.87 million, and net loss per share was USD 0.24, compared with USD 0.22.
Operating Expenses
Research and development expenses were USD 5.15 million, compared with USD 5.08 million, and general and administrative expenses were USD 4.59 million, compared with USD 4.48 million. Total operating expenses and loss from operations were USD 9.74 million, compared with USD 9.56 million.
Total other income, net, was USD 24 thousand, compared with other expense, net, of USD 496 thousand. Interest income was USD 19 thousand, compared with USD 95 thousand. Weighted average shares outstanding were 127,892,383, compared with 101,315,089.
Nine-Month Results
For the nine months, Research and Development expenses were USD 13.97 million, compared with USD 9.80 million, and general and administrative expenses were USD 14.44 million, compared with USD 9.44 million. Total operating expenses were USD 28.40 million, compared with USD 19.24 million.
Cash and Liquidity
Cash and cash equivalents were USD 2.43 million at September 30, 2026, compared with USD 5.20 million at the prior Balance Sheet date. Other receivables were USD 1.20 million, compared with USD 573 thousand, and prepaid expenses were USD 1.64 million, compared with USD 1.07 million. Total current Assets were USD 5.27 million, compared with USD 6.84 million.
The filing states that, based on the current operating plan, existing cash resources, even when considered together with Capital that may be raised under its Equity distribution arrangements, are not sufficient to fund planned operations for at least twelve months. Share-based compensation was USD 2.03 million for the quarter, compared with USD 2.57 million.
On April 6, 2026, the company entered into an Open Market Sale Agreement with Jefferies LLC, which allows it to sell shares of common stock with an aggregate offering price of up to USD 75.0 million. The filing states that funding received was nil for the three and nine months ended September 30, 2026.
The filing states that in the first quarter of 2026 the company received Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI for the treatment of patients with KRAS-mutant, microsatellite stable metastatic colorectal cancer in the second-line setting. As of September 30, 2026, the company was committed to payments of approximately USD 144 thousand for activities mainly related to its clinical trial and Manufacturing programs.
Oncolytics Biotech Q3 2026 Earnings: Key Takeaways
Oncolytics Biotech reported a third quarter 2026 net loss of USD 9.71 million and a loss per share of USD 0.08. Cash and cash equivalents were USD 2.43 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...